Health-related Quality of Life After Breast-conserving Surgery and Intraoperative Radiotherapy for Breast Cancer Using Low-kilovoltage X-rays
Overview
Authors
Affiliations
Background: Intraoperative radiotherapy (IORT) is currently being evaluated as a novel approach during breast-conserving surgery (BCS). IORT can be used either as a tumor bed boost followed by external-beam radiotherapy (EBRT) or as a single treatment. In a matched-pair study, we assessed quality of life (QoL) in 69 patients with early breast cancer treated with BCS and/or IORT and/or EBRT.
Methods: Patients were matched for age and time since BCS. IORT was provided with 50 kV x-rays (Intrabeam) delivering 20 Gy at the applicator surface. EBRT (46 to 50 Gy in 2-Gy fractions in the IORT with EBRT group, and 56 Gy in 2-Gy fractions in the EBRT group) was initiated after completion of wound healing and/or chemotherapy. The mailed questionnaires included the European Organization for the Research and Treatment of Cancer QLQ-C30 and BR23, FACT-F, HADS, Body Image Scale, and Rosenberg Self-Esteem Scale. At 18 to 70 months' follow-up (median 47 months), all patients were disease free.
Results: We found only a few differences between the three groups. There was a trend toward more pain (mean ± standard deviation; 42.8 ± 32.9 vs. 27.5 ± 34.7) and reduced QoL (57.6 ± 20.7 vs. 70.3 ± 23.9) after IORT with EBRT compared with EBRT, respectively. IORT patients reported comparable QoL (70.3 ± 23.0), and less breast symptoms and body image concerns compared to EBRT (8.6 ± 12.3 vs. 19.2 ± 23.8, and 1.7 ± 3.3 vs. 3.4 ± 4.4, respectively). IORT alone resulted in significantly fewer breast symptoms (8.6 ± 12.3; P = 0.012) and less pain (23.9 ± 24.5, P = 0.041) compared with IORT with EBRT (26.1 ± 27.6; 42.8 ± 32.9, respectively).
Conclusions: Patients with early breast cancer after BCS and IORT with or without EBRT present with comparable QoL like patients receiving EBRT without a boost. IORT patients show the lowest rate of breast symptoms.
Burkon P, Selingerova I, Vrzal M, Holanek M, Coufal O, Polachova K Sci Rep. 2025; 15(1):1387.
PMID: 39779797 PMC: 11711455. DOI: 10.1038/s41598-025-85342-2.
Bagga S, Swiderska N, Hooker C, Royle J, Ennis-OConnor M, Freeney S BMJ Open. 2024; 14(8):e081222.
PMID: 39164104 PMC: 11337679. DOI: 10.1136/bmjopen-2023-081222.
He J, Chen S, Xu R Ann Surg Oncol. 2023; 30(13):8453-8454.
PMID: 37540328 DOI: 10.1245/s10434-023-14057-3.
He J, Chen S, Ye L, Sun Y, Dai Y, Song X Ann Surg Oncol. 2023; 30(13):8436-8452.
PMID: 37507556 PMC: 10625949. DOI: 10.1245/s10434-023-13955-w.
Sarria G, Ramos M, Palacios A, Castillo R, Castro F, Calvo A Front Oncol. 2022; 12:850351.
PMID: 35371998 PMC: 8968081. DOI: 10.3389/fonc.2022.850351.